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Abstract: This contribution emerged from an open, and continuing, discussion 
between a chemist and a philosopher, which resulted in a common awareness of the 
importance of trusting objects.  The purpose of this biography of a molecular object – 
cyclodextrin – is both descriptive and normative. Descriptive: to understand how a 
thing can become an object of trust or/and distrust. The biography reveals three 
layers of valuation sustaining the process of generating trust: reputation, semiosis, 
and ontology. The first one acts at the level of actors’ strategies and their interplay 
with regulations, the second operates with value-laden images conditioning the 
actors’ expectations, and the last concerns the changing relationships between CD-
technology and nature. As to the normative purpose, we aim at evaluating these 
valuations in order to allow critical trust generation. Finally, we try to appraise how 
nanotechnology reconfigures trust in objects by bringing visibility to the valuations. 
Keywords: cyclodextrin, molecule, chemistry, biography of objects, nanomedicine, 
trust, confidence, Luhmann, Dewey. 
Introduction 
In this paper, we tell the story of a little observed yet widely applied tiny little thing, a 
molecule named cyclodextrin (CD). During the second half of the 20th century, the image 
of CDs has shifted from toxic yet interesting molecules to trustworthy molecules that 
could be used in a great number of invasive applications. In following the various 
objectifications of this molecule in multiple scientific communities, contexts of 
application and research trends, our story narrates the adventures of trust in cyclodextrin. 
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Because of its relational and partly emotional nature, trust is an elusive concept. But 
it is nevertheless essential to any society. As Niklas Luhmann (1979, p. 4) put it,  
 
Trust, in the broadest sense of confidence in one’s expectations, is a basic fact of social 
life. In many situations, of course, man can choose in certain respects whether or not to 
bestow trust. But a complete absence of trust would prevent him even from getting up in 
the morning. 
 
As it will be recalled by referring to theories of trust – such as Luhmann’s – it is less 
than obvious that one can talk about ‘trust in objects’: Trust is supposed to be at play only 
in interpersonal relationships, in which objects are mere puppets in the hands and 
discourse of humans.  However, we will argue that some presence and depth can be 
allocated to objects in the generation of trust by resorting to the trope of biography. By 
making a biography of cyclodextrins, our aim is both descriptive and normative.  
Descriptive: to enquire into the process by which a thing becomes an object of trust.  
Normative: to critically evaluate the valuations that sustain this process. Finally, we will 
try to appraise how nanotechnology reconfigures trust in objects by making visible its 
valuations. 
1. Cylodextrins 
1.1. Introducing the Object 
Cyclodextrins are a family of compounds made up of sugar molecules (α-D-
glucopyranoside) bound together in a ring. Produced from starch (amylum) by enzymatic 
conversion, they are sometimes called ‘cycloamyloses,’ and formerly ‘cellulosine’ when 
first described by A. Villiers in 1891. The typical and most widespread CDs are the α- (6 
sugar units), β- (7) and γ- (8) cyclodextrins (figure 1) which, with their truncated cone 
shape (figure 2), have two major properties:  
- As they are hydrophobic inside and hydrophilic outside, they are able to form 
‘inclusion complexes’ in water, i.e. they are able to ‘encapsulate’ another molecule 
in their central cavity. As a result, a hydrophobic molecule will become more soluble 
when ‘complexed’ with CDs (figure 3).  
- Due to the presence of hydroxyl functions (–OH) along the molecule, they can be 
grafted, combined, and re-assembled with many different molecular compounds 
(Monza da Silveira et al., 1998; Boudad et al., 2001; Chen et al., 2009; 2010; Harada 
et al., 2009), including biomolecules: peptides, antibodies, proteins, vitamins, DNA, 
etc. (Pun et al., 2004; Davis et al., 2004; Choisnar et al., 2006; Chen and Liu, 2010). 
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Figure 1. Chemical structure of the 3 typical native/parent CDs (Harada et al., 2009). 
 
 
 
 
 
 
Figure 2. CDs’ truncated cone shape (original picture, M. Normand). 
 
 
 
Figure 3. Formation of an inclusion complex with a hydrophobic molecule and a hydrophilic CD (Szejtli, 1998). 
 
Due to these abilities, cyclodextrins are today perceived as ‘dream molecules’ for the 
development of applications in nanomedicine, such as targeted drug delivery systems and 
biosensors for molecular diagnosis (Uekama et al., 1998; Irie and Uekama, 1999; Cryan 
et al., 2004; Maestrelli et al., 2006; Trapani et al., 2008; Bayley et al., 2009; Couvreur et 
al., 2010; Ortiz Mellet et al., 2010). 
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1.2. Trust Issues  
How, then, can the broad concept of trust be applied to a tiny little thing such as 
cyclodextrin?  
Trust emerged as the central issue in the course of our discussions on Mickaël 
Normand’s own work. His Ph.D. focuses on the aim of synthesizing the prototype of a 
biomedical drug-release device using β-cyclodextrin. Though Normand’s research is not 
aiming at delivering ready-to-use products for a determined therapy, it nevertheless 
contributes to establishing the basic synthetic route for a new generation of CD-based 
nanocarriers allowing time and/or site control of drug delivery in the human body. The 
process consists of graft polymerization of a biodegradable and biocompatible monomer 
to improve β-CD human-body tolerance. Normand’s work can thus be seen as an attempt 
to develop ‘safety by design’ materials (Kelty, 2009; Kelty and McCarthy, 2010). But if 
β-CD human-body tolerance has to be improved, does that mean there is something 
wrong with the molecule?  
We quickly acknowledged that this question could not be answered purely in terms 
of safety. Issues of trust stood out as a precondition for safety: Not only do scientists 
want their objects to be safe; they want them to be perceived as safe; they want objects to 
be trusted. But in appealing too obviously to people’s confidence they risk to be 
mistrusted: Here is the dilemma of trust, and the very reason why trust cannot be reduced 
to safety, control, or security. One cannot establish trust by merely providing control, 
because to bestow trust implies the awareness of the trustor’s vulnerability to the trustee 
(Baier, 1994). Whilst nanotechnology pursues the dream of achieving unprecedented 
control of matter and processes at the molecular scale, it seems very questionable that it 
could establish something as ‘trust by design’ on the model of ‘safety by design’ (by 
which a social preoccupation is transformed into a scientific question). Trust, unlike 
safety or reliability, cannot plausibly be ‘embedded’ in objects. It thus seems unlikely 
that objects could be characterized as objects of trust or distrust.  
And yet, the case of CDs seems to be a counter-example. CDs are ‘Generally 
Recognized As Safe’ by the US Food and Drug Administration (FDA), and they are 
already widely applied for pharmaceuticals, food, cosmetics, toiletry and perfumery 
commodities, and even tobacco. The CD-related literature suggests, however, that CDs 
have raised issues of toxicity. Today, a broad consensus exists that “any of their toxic 
effects is of secondary character and can be eliminated by selecting the appropriate CD 
type or derivative or mode of application,” and, as a result, that “CDs can be consumed 
by humans as ingredients of drugs, foods, or cosmetics” (Szejtli, 1998, p. 1743).  
Although chemists assume that CDs are sufficiently harmless for human consumption, 
they had to learn to ‘fine-tune’ the articulation of the molecule’s toxicity levels to make 
CDs safe for the specific kinds of application considered. They had to establish CDs as 
objects of trust. 
2. Historical Background 
In this section we provide a historical outline of CD molecules. József Szejtli, a leading 
figure in the CD community, who will be discussed later, distinguished three epochs 
(Szejtli, 1998): a discovery period (1981-1930s); systematic studies on CDs (1930s-
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1970s); and industrial production and utilization of CDs (from the 1970s onward). 
Because this periodization conceals important points2, we propose a different one. 
2.1. A Scientific Success (1891-1950s) 
The first phase follows the standard pattern of chemical discovery: First, the extraction of 
a new product from a familiar material (starch); then, the discovery of interesting 
properties (i.e. the formation of stable complexes with organic compounds); finally, the 
explanation by the underlying molecular structure. 
In 1891, the French microbiologist Villiers, working on the digestion of potato starch 
by Bacillus amylobacter, isolated two kinds of crystalline dextrins (i.e. derivatives of 
glucose) he called ‘cellulosine’ because they displayed properties similar to cellulose 
(Villiers, 1891). Then, in 1903, whilst studying microbes thought to be responsible for 
certain food poisoning, Schardinger reported the formation of two different crystalline 
products seemingly identical to Villiers’ ‘cellulosine:’ α- and β-dextrin (Schardinger, 
1903). For decades, the ‘Schardinger dextrins’ were studied: Pringsheim emphasised their 
tendency to form complexes with various organic compounds (Pringsheim, 1928; 1932).  
In 1936, Freudenberg and co-workers postulated cyclic structures (Freudenberg et al., 
1936). ‘Schardinger dextrins’ became ‘cyclodextrins’. In 1948, the same group dis-
covered γ-cyclodextrin (Freudenberg and Cramer, 1948).  At this time, the mechanism by 
which a hydrophobic molecule, depending on its size, can be inserted into the central 
cavity of CDs – thus forming an inclusion complex thermodynamically more or less 
stable – is elucidated and identified as a well-established structure.  
2.2. From Confidence to Suspicion (1950s-1970s) 
In the early 1950s, two groups took on a leading role in CD-Research: Friedrich Cramer’s 
group in Germany and Dexter French’s group in the US.  While French and co-workers 
were working on ‘many many CDs’, and discovered larger molecule complexes, 
Cramer’s group research was more specifically directed toward inclusion compounds 
(Cramer, 1954). 
Their firm confidence in the industrial potential of CD is well attested by the first 
patent published by Cramer, Freudenberg and Plieninger about CD-complexation 
(Freudenberg et al., 1953). The patent covered practically all of the most important 
aspects of CD application in drug formulations (enhancement of drug’s solubility and 
stability, protection against atmospheric oxidation, etc.) and established CDs as highly 
promising molecules for pharmacological applications.  
Nonetheless, a couple of years later, in the first fundamental monograph on 
‘Schardinger dextrins’ (French, 1957), French mentioned that, in some unpublished 
attempts of his group to investigate the ability of animals to metabolize β-dextrin, he had 
fed rats who died a week later. Was this a story forged to discredit the large patent 
obtained by the rival group? These results were not documented, and according to Szejtli, 
this review, otherwise excellent, had a huge negative impact on the image of CDs, which 
came to be seen as highly toxic molecules that should not be used in vivo. Indeed, the 
1953 patent never found any industrial application (Cramer, 1987).  
                                                          
2
 Especially Szejtli’s own role in the large-scale commercialization of CDs. 
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2.3. ‘Better Living With… Cyclodextrin’ (1970s-2000) 
Surprisingly, twenty years later, CDs came to be used everywhere, in many invasive 
applications, especially in Japan, and to a lesser extent in Europe and the USA.   
- In the pharmaceutical field, CDs are used as excipients to improve the solubilisation 
and stabilization of drugs; as capsules (molecular entrapments) to enhance bio-
availability and pharmacokinetics, to help avoid digestive problems, and to allow 
new solid phases or water-activated forms. We find CDs in vasodilators, antibiotics, 
anti-fungal drugs, anti-inflammatory drugs, eye-drop solutions and agro-chemicals. 
- In the food industry CDs are used to encapsulate, carry and stabilize flavour, colours, 
vitamins and fatty acids; to sequestrate, mask or reduce undesirable taste/flavour; to 
lengthen chewing-gum’s taste; to encapsulate ‘bad’ fatty acids such as cholesterol in 
mayonnaise and butter; to improve shelf-life of food products; to protect products 
against oxidation, decomposition, heat-induced or light-induced changes; and to 
emulsify/solubilize ‘alcopops’ (powder alcohol). However, with food industry, it is 
becoming harder to determine exactly in which products CDs are used, as unlike 
drugs, for which all ingredients have to be listed and registered in official 
pharmacopoeias, food products have no such labels. 
- Cosmetics and toiletry industries were the first ones to develop CD-applications 
(Duchêne, 1986). It is now the biggest market3 for CDs, which are used for ‘odour 
control’ in perfumes or laundry detergents, or can be found in shampoos to reduce 
their irritant effect. In the case of cosmetics and toiletry goods, the question of CD-
traceability is even further complicated, because CDs are often given brand names, 
such as Clenzaire™, the ‘secret’ and almost magical ingredient of Procter & 
Gamble’s multi-use freshener Febreze®. “Clenzaire™”, an advertisement on 
Amazon.com reads, “is the unique new formula from Febreze® that eliminates odors 
on fabrics better than ever before. Clenzaire™ surrounds odors and sweeps them 
away, leaving your home noticeably fresh wherever you use it.”  
- Other uses include: tobacco industry, for the entrapment of aromas activated by 
combustion, and the sequestration of nicotine and tar; chemical industry, for 
solubilization and solidification; and textile industry, for fragrance delivery and 
malodor control. In Szejtli’s fertile imagination, CDs could bring about a revolution 
in textile industry by providing ‘pharmaceutical clothes’ for transdermal delivery 
(Szejtli, 2004, pp. 1836-37).  
In short, this narratives suggest that CDs entrap the ‘filthiness’ and make life ‘more 
fluid’. With CDs, fats become dietetic, detergents good for you, smoking healthier... 
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 “About 70% of all cyclodextrins produced are used in this field. (…) single toiletry product, like a 
fragrance tissue, or a deodorant spray for furniture, curtains, or carpets, which need no health authority 
approval because it is not consumed by humans and is used only in laundries, requires hundreds of tons of 
βCD or hydroxypropyl-βCD every year” (Szejtli, 2004, pp. 1839-40). 
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2.4. Supramolecular Research (from the 1990s) 
In academic scientific research CDs fall under the umbrella of supramolecular chemistry4 
by epitomizing most of its core features:  
- a ‘host-guest system’ (thanks to their ability to form inclusion complexes with a wide 
range of compounds);  
- interlocked molecules such as catenanes and rotaxanes (Nepogodiev and Stoddart, 
1998);  
- scaffolds and templates to self-assemble supramolecular architectures (Easton and 
Lincoln 1999);  
- biomimetism, with CDs mimicking “the cooperative ‘multimode, multipoint’ 
binding often observed in biological systems” (Chen and Liu, 2010).  
2.5. Entering the Nanorealm (from the 2000s) 
But how has nano contributed to the dream of ‘wonderful’ CD molecules? For one, it did 
not increase the number of industrial applications, which were already numerous. 
In the early 2000s, the anticipated demise of the blockbuster model in 
pharmaceutical industry fostered intensive academic research on nanovectorization.5 It 
was expected to use old active principles that have too many secondary effects or cannot 
go through biological barriers with classical medicines. The interest of CDs has also been 
emphasized in bio-sensing and DNA-chip sequencing, e.g. with individual CDs used to 
slow down and to measure DNA base traffic in a nanopore (Bayey et al., 2009). Besides 
the biomedical domain, possible uses of CDs have been reported in molecular electronics, 
e.g. with CDs threaded around organic conductors for the assembly of single insulated 
molecular wires (Anderson et al., 2002).  
The nanotechnological use of cyclodextrins mainly features in the functional 
individualisation of the molecule. The CD molecule, or CD-conjugated molecular 
system, is thereby ‘sold’ for itself and no longer as a mere ‘ingredient’ in a bulk material.  
Especially in nanomedicines CDs are no longer excipients in a bulk formulation of the 
drug, but individual objects acquiring their own pharmacological identity or partaking in 
the production of a pharmacological effect.  
3. Trust, Confidence, and Objects 
So, what happened?  How could the image of CDs have shifted from toxic yet interesting 
molecules to trustworthy molecules that could be used in a great number of invasive 
applications? And to what degree can we talk about trust here? To understand the 
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 According to Lehn (1987), “supramolecular chemistry may be defined as ‘chemistry beyond the 
molecule’, bearing on the organized entities of higher complexity that result from the association of two or 
more chemical species held together by intermolecular forces. (…) One may say that supermolecules are 
to molecules and the intermolecular bond what molecules are to atoms and the covalent bond.” 
5
 Nanovectors are not new: Their concept can be traced back to one of a ‘magic bullet’, proposed by Paul 
Ehrlich (1854-1915), known as the father of chemotherapy (Kreuter, 2007). The first development of 
nanoparticles for drug delivery and vaccine purposes are due to Peter Speiser and his team at ETH Zürich 
during the 1970s (Kramer, 1974; Kopf, 1975; Kopf et al., 1976; 1977; Marty, 1977; Marty et al., 1978).  
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difficulties posed by ‘trust in objects’ it is necessary to make a brief incursion into 
theories of trust (Luhmann, 1979; 1988; Gambetta, 1988; Giddens, 1990; Baier, 1994; 
Hardin, 1996; Misztal, 1996; Nooteboom, 2002).  
3.1. Theories of Trust  
Most theories of trust, if not all, agree that trust is only at stake in interpersonal 
relationships when ‘an agent assesses that another agent or group of agents will perform 
a particular action’ (Gambetta, 1988). Following Luhmann, risking trust is an option that 
presents itself in situations of opaqueness of the other’s will, whereas trust in a system or 
a mechanism should be called ‘confidence’. Trust is deeply linked with contingency, 
freedom and risk. Indeed, we speak of ‘trusting someone’s choice,’ which is contingent 
and subjected to uncertain opinions, whereas we speak of ‘being confident in someone’s 
knowledge,’ which can only be what it is. 
The distinction between trust and confidence is the basis of Luhmann’s work on 
trust. For him, trust presupposes awareness of risk, whereas confidence does not.  
“Confidence, as Luhmann uses it, refers to a more or less taken-for-granted attitude that 
familiar things will remain stable” (Giddens, 1990, p. 31). It is involved in expectations 
where disappointment is a possibility that can reasonably be neglected, or avoided by 
filling knowledge gaps. But the difference is qualitative; it is not a matter of probability:  
Trust is involved where one decides to cope with the freedom of others by assuming a 
risk. For instance, if I buy a used car instead of a new one, I risk purchasing a dud. But 
here, I place trust in the salesperson and not in the car. If the car is a dud, I may regret 
having placed trust in someone, but I partly shoulder the blame. “The distinction between 
trust and confidence depends upon whether the possibility of frustration is influenced by 
one’s own previous behaviour and hence upon a correlate discrimination between risk 
and danger” (pp. 31-32). According to Luhmann’s definition of trust, asking how 
relations of trust could be established between humans and objects would be a non-issue 
or else, in the case of ‘system trust’, an issue of confidence.  
Anthony Giddens’ account of trust is more problematic, since he distinguishes 
between ‘trust in people’ and ‘trust in abstract systems.’  While the former corresponds to 
Luhmann’s (1988) account of ‘trust’, the later is more akin to Luhmann’s concept of 
‘confidence’. Thus, Giddens never considers fully the case of ‘trust in objects’, since trust 
is for him “a particular type of confidence rather than something distinct from it.” For 
him, trust and confidence are connected with a more fundamental feeling of ‘ontological 
security’, where the two are not yet distinguished. But even though ‘ontological security’ 
is “a sense of the reliability of persons and things” (p. 92), it originates in the construction 
of personality and self-identity, and never in the design of objects: “Trust in the reliability 
of nonhuman objects, it follows from this analysis, is based upon a more primitive faith 
in the reliability and nurturance of human individuals” (p. 97).  
A concept of trust in objects may long be searched for in the theories of trust. And if 
it is occasionally mentioned, it is dismissed right away. For instance,  
One can have trust in things: one’s car, for example, with an expectation of performance. 
(…) [But] things are less interesting since they have no life or will of their own. 
Intentional trust does not apply. Trust associated with the actions and motivations of 
people, that is, behavioral trust, is more complicated, interesting and important. When the 
performance potential or quality of objects is difficult to judge, trust in objects may shift 
to trust in the provider of the object (Nooteboom, 2002, p. 55). 
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To speak about trust in a nonhuman entity would be nonsense or naïve 
anthropomorphism. ‘Trust in objects’ is systematically relegated to confidence, or worst, 
to trust in experts: ‘You can rely on a technology, but only trust experts’ (Åm, 2010).  
3.2. From Motivations for Trust to Objects of Trust 
In order to talk about ‘trust in objects’, we need to decentre the focus. Such a decentring 
has been advocated by Trond G. Åm in a recent contribution on ‘Trust in 
Nanotechnology’ (Åm, 2010). 
Åm criticizes sociological ELSI6 surveys addressing trust in nanotechnology in terms 
of ‘public perception’: He argues that they tend to create ‘forced relationships’ to 
nanotechnology in order to compensate the lack of people’s familiarity to it. For example, 
they may call for more involvement of lay people in the evaluation of concrete 
applications, which should help respondents relating nanotechnology to their everyday 
life, and then they measure the amount of public trust in nanotechnology.  By doing so, 
he claims, these studies feign to predict where trust and distrust are likely to arise.  But 
nano-containing products may still change name in response to public’s distrust. Thus, 
the lability and invisibility of nanotechnology prevent these surveys from achieving the 
‘social robustness’ they aim at.  
It is not enough to try to avoid the abstraction caused by unfamiliarity by presenting 
people to products ‘close to everyday life’. Whereas [these studies] focus on enriching 
our understanding as if the entities of the relationship were given – that of 
nanotechnology and the public – by mapping attitudes and motivations for trust in this 
particular relation, the problem (…) lies in understanding how it is or becomes a relation 
in the first place, if at all. That is, whether it is a relation, how this relation emerges and 
how the establishing of the relation influences upon trust (Åm 2010). 
Moreover, by presupposing that trust is something necessary and good, these surveys 
leave no room for a critical kind of trust that would work, for example, in absence of 
confidence, or even in combination with distrust (Poortinga & Pidgeon, 2003). Subtleties 
of trust are spuriously reduced to the measure of the degree of public acceptance. 
Åm suggests that “the approach has to be widened and initially focus not on people’s 
motivations for trust but rather the object of trust itself.”  By this, he means both: 
- To reflect on the concept of trust, which should not be confused with acceptance, 
cannot merely draw upon earlier experiences in areas where there are well-defined 
questions, such as with GMOs or nuclear power, and cannot mean only 
‘participation’ regardless of the qualitative features of the technology involved;  
- To study “how an object of trust becomes an object of trust” emerging into 
relationships that stabilize the “character of the technology in question as an object 
of trust.” 
Åm’s main point is that the human/technology relationships where trust and distrust 
are likely to occur cannot be considered as given. Objects of trust are worth being studied 
as entities that emerge into relations, and which are inherently made of these 
relationships. However, this does not tell us what may qualify a thing to become an object 
of trust, and for whom. This opens up the issue concerning reasons for trust. 
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3.3. Who Trusts Who and Why? A Biographical Approach Towards Objects of Trust 
As Luhmann argues, we trust a person (or a thing) when we expect her (or it) to act or 
behave in a specific manner, although we are aware of the fact that she (or it) can act 
differently and frustrate our expectations. When we, nevertheless, choose to bestow trust, 
we do this because the trustee gives us reasons to trust them (or it), e.g. by their honesty, 
moral integrity, rationality, their previous behaviour in similar situations, and so forth.  
Note that this point is not about motivations for trust on the part of the truster (for 
instance friendship with the trustee), but about reasons to be trusted on the part of the 
trustee. Unlike motivations, reasons of trust are in connexion with the character of the 
trustee, here with the object in question. 
Hence it is not enough to say that objects of trust emerge in relationships. There are 
some relationships that may matter more than others, or that may matter differently to 
different people. The problem is to know whether these relations of trust are appropriate 
reasons for trust, and for whom they might be so, since one of the difficulties with trust is 
that while one person may trust another a third will not because he or she does not find 
sufficient reasons to trust this person. As John Dewey put it, “a valuative judgment is 
therefore not a mere statement that a certain thing has been liked; it is an investigation of 
the claims of the thing in question to be esteemed, appreciated, prized, cherished” 
(Dewey, 1925, p. 96). 
One way to address this issue – that is, to allow shifting from a descriptive to a 
normative account of ‘trust in objects’ – is resorting to Dewey’s distinction between 
‘valuing’ and ‘evaluating’ (Dewey, 1939). Indeed, Dewey draws at the same time a 
contrast and a continuum between these two kinds of valuation judgments. Valuing (or 
prizing) refers to one’s attitude of caring for or holding precious a certain thing that one’s 
estimates link to some consequences or/and conditions into which one holds an interest.  
Valuing thus consists of one’s situated actions of striving to maintain, foster or procure 
the estimated conditions for the existence of this thing. Despite the personal and affective 
nature of the link between the valuator and the object, such a judgment is nevertheless a 
behavioural attitude that is utterly observable. Moreover, since the valuation is about a 
certain situation for which one infers a certain connectedness between the conditions 
and/or consequences that matter for oneself and the existence of the thing in question, 
Dewey assumes that it can be rendered public and testable by an enquiry that brings into 
existence both the ‘end-in-views’ and objects of valuation. Such an epistemic enquiry into 
the conditions, connections and possible consequences constitutes the becoming-public of 
the process of valuation; it thus tends to enable judgments of evaluation (or appraising), 
which are judgments about valuations.  These “propositions about valuations (…) are 
valuation-propositions only in the sense in which propositions about potatoes are potato-
propositions” (p. 39)7. Evaluations, or appraisals, are thus primarily concerned with the 
relational properties of objects becoming public.  
Since cyclodextrins have given rise to a number of various trust-valuations by an 
heterogeneous array of actors, resorting to the trope of a biography may be a convenient 
method to join together the multiple voices that ‘claim’ the thing. Making a biography of 
an object means dealing with history as well as with memory and forgetting (Poirot-
Delpech, 2009). A biography of an object is neither mere subjective account nor pure 
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 For our case study, Dewey’s potato-sentence could be rephrased as follows: “[P]ropositions about trust-
valuation of CDs are valuation-propositions only in the sense in which propositions about CDs are 
cyclodextrin-propositions.” 
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succession of objective facts; it is the pragmatic construction of a narrative plot where 
value assignment partakes in the thing’s objectification instead of being considered as a 
secondary projection on some objective facts; it can be construed as a ‘practice of 
mattering’ (Barad, 1998) in which humans’ valuations are interwoven with the various 
materializations of the object. Furthermore, a biography epitomizes a certain character.  
A character (ethos) is a set of dispositions, e.g., of acquired tendencies to produce effects 
and actions in specified ways. Moulding and appraising the character of a thing is 
basically what any chemist does (synthesis and characterization). As characters of fiction, 
chemical things can acquire a consistent character while still existing in dependency of its 
‘characterisers’: Those who manipulate them, relate to and narrate them. Last but not 
least, a biography of an object does not have to be an ‘apology’ or a ‘hagiography:’ It 
should enable critical evaluation of the object and of its valuations – critical trust 
(Poortinga & Pidgeon, 2003). 
In our case study, cyclodextrins have been loaded with trust-valuations into both 
material and social processes of valuation: Material (or technical, or chemical), by 
chemists’ achievements into tuning and modulating CDs’ natural toxicity; social, by the 
interweaving of the valuations that built CDs’ reputation, semantics and ontology. Both 
have contributed to rendering the character of the thing as an object that can ‘pretend’ to 
trust. Then, by bringing visibility to the trust-valuations loaded in CDs, it can be argued 
that CDs’ entrance into the nanorealm represents a ‘public test’ for the evaluation of 
cyclodextrins.  
4. The Valuations of Cyclodextrins as Objects of Trust  
Our aim now is to explicate the trust-valuations that have sustained the objectifications of 
CDs in multiple contexts of research and use. We distinguish three different layers: 
reputation (actors’ strategies and their stabilization in regulations), semiosis (the 
production of meaning through value-laden images conditioning the expectations placed 
in the object), and ontology (the changing relationships between CD-technology and 
nature).  
4.1. Reputation 
Generally, CD-development experts contend themselves with explaining the boom of 
CDs’ application with the increasing economic availability of CDs. Within 25 years the 
cost of CDs dropped from $2000 to $5 per kg. This drastic price drop, combined with the 
mechanisms of the market, would suffice to explain CDs’ diffusion in so many 
commodities.  According to Szejtli, if the market says ‘yes’, then the research is good and 
useful. 
(...) only the decision of the market is unambiguous. Is the newly developed product or 
technology useful or necessary? Does it represent real development?  If yes, the value of 
the invested work can be expressed in measurable parameters (mainly by money), if not, 
it will be forgotten (Szejtli, 2004, p. 1826). 
If we stick to the distinction between trust and confidence, one should speak of a 
strong confidence in the market’s ability to furnish an objective criterion of CD-
research’s value, rather than of trust. However, as simple as it seems, this rationale 
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conceals at least two things: First, the way CDs became available for mass-production; 
and, two, Szejtli’s own role in reshaping CDs’ reputation. 
For seventy years CDs could only be produced in relatively impure and small 
laboratory-scale amounts.  In 1939, biochemists Tilden and Hudson isolated the enzyme 
synthesizing crystalline dextrins from starch in bacteria Baccilus Macerans. They pre-
dicted the possibility of using the enzyme for commercial production of dextrins8. But 
this occurred only in the 1970s when the spread of genetic engineering enabled to mass-
produce CDs as pure materials from bacteria.  
The first plants were built in Japan, who became the first largest world consumer of 
CDs in the 1970s and 1980s (Hashimoto, 2003), probably because the controversy about 
their toxicity found very little echo in Japan. According to Lofstson and Duchêne (2007), 
“in Japan, there is a tradition for industrial usage of natural products and the Japanese 
regarded the parent cyclodextrins as natural materials originating from starch and thus as 
‘non-toxic’ natural products.” The first CD-containing pharmaceutical product, a 
vasodilator9, had been commercialized in Japan by Ono Pharmaceutical in 1976, only in 
1988 in Italia10, and then in 1997 in the USA with a formulation of β-CD in oral solution.  
Thus, when Szejtli entered the scene of CD-business during the 1980s, Europe and the 
US were lagging behind the Japanese for cultural rather than for economic reasons. In 
turn, this gap to be filled has brought the incentive that was just needed to stimulate the 
commercialization of CD-products. 
József Szejtli (1933-2004) was a Hungarian chemical engineer. He has been called 
‘the godfather of CD’, ‘the designer’ or ‘the international harmoniser.’ He organised the 
first CD-Symposium in Budapest in 1981. In 1985, he created a monthly newsletter 
surveying all CD-related literature, Cyclodextrin News and in 1988, wrote the first 
handbook on CD, Cyclodextrin Technology. From 1989, he was the founder and 
managing director of the CycloLab in Budapest, a private research organisation that 
became a centre for the technological transfer between CD research and industry.  
Without the immense efforts of this persevering man, CDs’ economical value would 
probably not have been such great. 
Szejtli’s strategy to reshape CDs’ reputation becomes apparent in the many reviews 
he wrote. The same claim can be found in at least eight of his writings: First, to remind 
the CD community of the ‘unfounded’ belief in toxicity of CDs that prevailed few 
decades ago; then, to denounce French’s total ‘misinformation’, which had lead to 
hampering of the CD-industrial development for decades (Szejtli and Sebestyén, 1979; 
Frömming and Szejtli, 1994, Szejtli, 1988; 1990; 1998; 2003; 2004; 2005). Szejtli 
reiterated that thanks to ‘adequate toxicological studies’ it has been demonstrated that 
CDs have no inherent toxicity to inhibit their widespread utilization. However, he never 
referred to these ‘adequate’ toxicological studies except in his own seminal book (Szejtli 
1988, p. 43) in which only one reference can be found: To one of his own previous 
studies (Szejtli and Sebestyén, 1979).  
Today, several toxicological properties of CDs are known: crystal precipitation and 
nephrotoxicity (Rajewski et al., 1995); influence on haemolysis (Panini et al., 1996); 
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 “The preparation of the characteristic amylases of these two bacteria is a relatively simple and 
inexpensive procedure, and the conditions established for maximal enzyme production and starch 
hydrolysis provide a basis for their possible commercial usefulness. The B. macerans enzyme, in 
particular, seems to have many theoretical applications to carbohydrate chemistry which merit 
consideration” (Tilden and Hudson, 1942, p. 543). 
9
 Prostaglandin E2/β-CD – Prostarmon ETM sublingal tablets. 
10
 Piroxicam/β-CD. 
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cytotoxicity (Kiss et al., 2007), among others. It is generally assumed that these effects 
can be masked or attenuated by using derivative (modified) CDs, and not parent (natural) 
ones. However, until the mid-1990s the quotation network of CDs’ safety evaluation 
studies had still been very limited and lead in most cases to Szejtli’s work.    
When discussing recent and emerging nanotoxicological issues it is often stressed 
that current knowledge is not sufficient to deliver unambiguous answers, which, for this 
reason, might be decades away and available only on a case-by-case basis. Highlighting 
knowledge gaps is a convenient way to postpone regulatory decisions. Yet twenty years 
ago in CD-toxicity studies, seeking integral knowledge of toxicological properties was 
not the problem. Instead, as there were some already developed applications for the 
molecule, the method was to strengthen CDs’ reputation by referring to a few, and very 
specific, former safe systems11.  
By the 1990s, these specific former safe systems aimed at replacing the commonly 
used surfactants for drug formulation that were found to cause anaphylactic reactions 
(Rajewski and Stella, 1996). A ‘call for new formulation’ was launched in order to allow 
the use of CDs in this pharmaceutical niche. The challenge was to allow their use for the 
most dangerous drug administration route: Parenteral use (injection), because it bypasses 
most of the body’s natural defenses. Toxicological tests were crucial for this challenge.  
At this time, a large number of papers and reviews were produced concluding that the 
toxicity of CDs can be tuned by using the proper one: Either a native CD or a modified 
one, depending on the considered administration route. Moreover, the oral uses of CDs 
that had already been developed and applied, due to past ‘laxity,’12 exhorted CD-
promoters to ‘count the chickens before they were hatched.’13  
But by the late 1990’s, the ultimate goal was to obtain FDA approval.  
Although a number of products containing cyclodextrins have been approved for human 
use in Japan and Europe, no product has yet to be approved in the U.S. The approval of 
specific products by the Food and Drug Administration (FDA) in the U.S. will be of 
paramount importance to the commercial viability of cyclodextrins for worldwide phar-
maceutical use (Rajewski and Stella, 1996, p. 1142). 
During those years, through the production of a series of reviews, chemists and 
biologists in effect operated as a cyclodextrin lobby. In many case, these reviews would 
conclude like this: 
It is accepted that the lack of an approved product by the FDA has probably inhibited the 
universal acceptance of cyclodextrins as pharmaceutical enabling agents. We hope this 
mini-review has helped answer some of the questions on the issues facing the 
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 From the 1990s to today, it is the four same systems based on CD derivatives: HPβCD (2-
hydroxypropyl-β-cyclodextrin), RMβCD (randomly methylated β-cyclodextrin), SBEβCD (sulfo-
butylether-βcyclodextrin) and HPγCD (2-hydroxypropyl-γ-cyclodextrin). As Irie and Uekama put it, 
“early studies showing the nephrotoxicity of the parent CDs limited administration routes (…). However, 
the recent availability of new CD derivatives with better safety profiles has renewed interest in extended 
uses of CDs administered by a variety of routes” (1997, p. 149). 
12
 “Most of the currently used pharmaceutical excipients were developed several decades ago when the 
regulatory issues, especially regarding toxicological evaluation, were much more relaxed” (Loftsson and 
Duchêne, 2007, p. 8). 
13
 “The industrial explorations of cyclodextrins have been hampered by toxicological evaluations, not 
because cyclodextrins are toxic but rather due to the high cost of proving that they are not” (Loftson and 
Duchêne, 2007, p. 8), followed by a reminder of French’s story and by references to Szejtli’s seminal 
studies. 
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pharmaceutical development and uses of the cyclodextrins (Stella and Rajewski, 1997, p. 
565). 
The FDA approval was finally given in 1997. It was followed by the FDA ‘Generally 
Recognized as Safe’ (GRAS) exemptions for γ-CD (2000), β-CD (2001) and α-CD 
(2004). The GRAS exemption claims that the use of the molecule is exempted from the 
premarket approval requirements of the US Federal Food, Drug, and Cosmetic Act. In 
effect, it has rendered CDs immune to further regulatory toxicological issues. Indeed, 
although CDs are listed on Japanese, European and US Pharmacopoeias, they are 
mentioned in the FDA’s list as ‘Inactive Pharmaceuticals Ingredients.’ As a result, the 
GRAS exemption allows CDs to be regulated as food additives, not as active substances.  
Herein lies the secret of ‘the universal acceptance of cyclodextrins as pharmaceutical 
enabling agents.’ 
The process related in this section was more a self-convincing construction of the 
benefit of the CDs than a purely ‘objective’ demonstration of the abilities and 
innocuousness of CDs for pharmaceutical applications – hence the references to the 
‘objectivity’ of the market mechanisms and to the respectability of the FDA approval. It 
was a trust built for, by and amongst the CD community while being built as a matter of 
confidence for the public. 
4.2. Semiosis 
As related in section 2.4, CDs epitomized perfectly the concept of ‘host-guest system’ 
popularized by supramolecular chemistry in the 1980 to 1990s. We claim that the images 
and the vocabulary used by supramolecular chemistry played an important role in 
revaluating CDs as an object-symbol.  
Significantly, cyclodextrins have been characterized and used as artificial chaperones 
(Akiyoshi et al., 2001) – natural host-guest systems that ‘help’ other proteins, denatured 
(unfolded) by thermal stress, to return to their functional state – an example of many 
showing how “through modifications, cyclodextrins can be invaluable in investigations at 
the frontiers of chemistry ranging from enzyme-like catalytic activity and antibody-like 
binding to aesthetically pleasing molecules” (Breslow and Dong, 1998). In supra-
molecular chemistry, CDs cheerfully interweave the cognitively useful and the 
aesthetically pleasing. 
The image of toxicity formerly associated with CD could be attenuated and 
superseded with connotations such as water-affinity, fluidity, softness, hospitality, 
stability, care and protection, the same connotations that were used for the marketing of 
CD-containing products such as Febreze®.14 Thus, even if supramolecular chemistry 
research was mainly academic and not applied research, it helped the molecule to be 
positively valuated regarding its use in in-vivo applications.  
Now, there is a stark contrast between the valuations of CDs conveyed by 
supramolecular chemistry and the valuations associated with nanovectors used for 
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 While the scientific controversy over CDs’ biotoxicity seems to have come to an end, a new 
controversy surfaced on a different scene about what can be called the ‘Febreze® rumour.’ Indeed, a 
considerable amount of concern is expressed online about the presumed danger of the freshener regarding 
pets: Some people complain that their pet has been killed by Febreze®, others seek to use it in order to kill 
unwanted insects and domestic pests; some says that it is just an urban legend. Whether people, discussing 
the toxicity of their favourite household freshener, ever heard about cyclodextrins or not, the ‘Febreze® 
rumour’ looks like a lay re-enactment of ‘French’s rats rumour.’ 
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targeted drug delivery: ‘intrusiveness’, ‘stealth kill’, ‘nanomissiles’, ‘homing devices’, 
‘one target, one bomb’, ‘surgical strike.’15  Symbolized by the arrow, nanovectors rhyme 
with Terminators, robots programmed to kill whilst never missing their target.  
Are the changing valuations attached to CDs pure rhetoric? Before criticizing these 
images as being value-laden, one first needs to consider their role: These images of 
invisible objects are observable valuations; they create a moral landscape that conditions 
the expectations actors place in the object. Following Dewey (1939), making the 
valuations explicit may stage the ground for their evaluation (conscious and reflexive 
moral judgment). However, appraising the value-laden content of these images also 
allows for finding better images (new valuations). For example, although the widespread 
used metaphor of ‘homing devices’ may be fully justified to the eyes of the ‘crusaders’ 
involved in the ‘war against cancer’, it obfuscates the very mode of operation of these 
objects: Indeed, with nanovectors, the formulation of a drug is no more a passive vehicle; 
it acquires its own kind of activity in the organism during the entire drug’s trajectory.  
Unlike homing devices, these objects are not riveted on their target, crossing an 
indifferent space. They would be more like ‘secret agents’, designed to infiltrate a series 
of biological milieus by manipulating metabolic interactions in order to elude, or to cheat, 
immune detection and response systems. Whilst one image may be neither true nor false 
there are some images that are better than others. Here, the choice between the two 
object-symbols depends on whether one is seeking to privilege blind confidence – for the 
sake of therapeutic efficiency, perhaps – or critical trust.   
4.3. Ontology 
Moreover, these valuations involve deeper aspects that should not be neglected.  
Ontological features are also at stake here. All along this storyline, the relationships 
between CD-technology and nature are constantly reconfigured, and these changes match 
with various dimensions of trust (Poortinga and Pidgeon, 2003).  
Arguably, starch chemists of the 1950s expressed confidence in Luhmann’s sense in 
the industrial potential of CDs rather than trust: At the time, the boom of industrial 
outcomes was considered to be a kind of deterministic process. It was an expectation 
grounded on the natural origin of CDs, the rational knowledge of its structure-properties 
relationships, and its scientific success. CDs were expected to fulfil their industrial 
potential in the same way they had their scientific potential, and the chemists’ confidence 
in CDs rested on a view of their ‘good nature.’  
However, along with confidence came suspicion: ‘Natural’ came to be conflated with 
‘toxic’, and the view of CDs’ ‘good nature’ could no longer be sustained.  
This resulted in a lack of confidence – but perhaps not distrust, since it did not 
withdraw actions. Later on, when synthetic CDs were developed – using biological 
engineering, CDs were considered to be semi-natural products that could be trusted if 
modified in order to be safe and if engineered in order to serve specific applications.  
Subsequently, during the rise of supramolecular chemistry, modified CDs served as 
simplified systems to emulate biological guest-host interactions. Re-envisioned as 
biomimetic systems, CDs were not merely naturalized:16 They played the role of 
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 It is odd to notice that the concept of ‘surgical strike’, after having transferred from medicine to war, 
finally reintegrates into medicine, loaded with a bellicose meaning. 
16
 A defining feature of biomimetism is that it supposes a differentiation between artefacts and their 
natural analogoï and does not mean making indistinguishable copies (Bensaude-Vincent, 2009). 
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mediators between humans and nature. Furthermore, CDs were communicative tools 
between scientists from different fields, allowing the development of an interdisciplinary 
network of trust between chemistry and biology, and between academic and industrial 
uses. CDs became objects of trust by bridging two kinds of relationships: human-object-
nature, and human-object-human.  
At the same time, this resurgence of the reference to nature has resulted in a new 
naturalization in the CD-marketing discourse, reminding people of CDs’ ‘natural 
blessings.’ It was trust stabilized and re-naturalized in confidence. Even for chemists 
using highly reengineered CDs, the industrial success of CDs could thus legitimately be 
referred to the natural origin of CDs. For example,   
Fascinating compounds including enzyme mimics, abiotic receptors, fluorescence 
indicators and molecular actuators, have been obtained (…). Being of natural origin, 
organic, biocompatible substances, CDs seem to have a unique status, and it is difficult to 
find any group of chemical products (drugs, cosmetics, food, plastics, paper, textiles, 
pesticides, etc.) or processes (formulation, catalysis, separation, stabilization, etc.) 
without convincing examples for the use of CDs (Bellia et al., 2009). 
Finally, with all the hype and promises about nanomedicine, emphasis lies on the 
potential of tailor-made CDs to overcome nature’s limitations. Of course, the wish to 
dispose of an indefinite number of tailored CDs enabling all possible combinations in 
order to achieve definite functions is not new17, but the quest for nanovectors re-enacts it 
with an unequalled virulence. The attempt to get rid of nature’s limitations by 
establishing an unprecedented control of molecular processes appeals to confidence, and 
even overconfidence, more than to trust.  
5. How the Nanorealm Reconfigures Trust in Objects  
We have argued that three layers of valuation – reputation, semiosis, and ontology – have 
contributed to cement CDs’ character as an object of trust or distrust. On each of these 
layers, CDs have acquired a set of dispositions resulting from a more or less stable 
compromise between human strategies and material processes. Focusing on nanovectors 
– one particular field of nanotechnology where CDs are seen as promising – we are now 
aiming at appraising how nanotechnology reconfigures trust in CDs.  
5.1. The Revenge of Galenics 
In pharmaceutics, the ‘nano-turn’ concerns less what is administered than the mode of 
administration of the drug. In other terms, it aims at designing new medicinal forms 
rather than new drugs. It is, or it could be, a revolution in Galenics, not in pharmacology 
per se. 
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 ‘Several chemists who have not been satisfied with what nature has provided with cyclodextrins away 
at this monumental task. It is to the credit of these people that a variety of new cyclodextrins are now 
available (…).  Cyclodextrins have thus been called structural and functional straightjackets. It is a credit 
to those who have catapulted these unusual molecules to such prominence despite their limitations. It is 
mind boggling to think of the progress that could be made if cyclodextrins of any size, shape, and most 
importantly containing any functional groups were available’ (Khan et al., 1998). Today, twelve years 
later, only the same four modified CDs are industrially available. Since then, the development of tailor-
made CDs with properties on demand has not fulfilled its promises at all. 
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Named after Galen of Pergamon (physician, surgeon and philosopher of the 2nd 
century), Galenics is the art of incorporating active principles into medicinal forms 
suitable for administration (pill, tablet, capsule, syrup, infusion, aerosol, inhaler, liquid 
injection, powder, crystal, gum, cataplasm, cigarette, etc.). Galenics has often been 
despised by bioscience-based pharmacology as a mere ‘technical’ science, or worse, as a 
kind of ‘marketing’ dealing with the drugs’ ‘presentation’ (form, colour, encapsulation, 
packaging, etc.). Significantly, it is most often called ‘pharmaceutical technology’ in 
English. The external aspect given to a drug is yet crucial to introduce it in everyday life 
and to favour the accomplishment of the technical gestures one has to perform when 
taking a medicine. The Galenic form is thus essential for both the materialisation and 
socialisation of drugs (Rasmussen, 2005): It allows standardisation of doses, stabilisation 
and conservation of active substances; it has an impact on the drug release profile 
(bioavailability and time) as well as on its therapeutic index. Finally, it could be said that 
galenics allows transforming a mere ‘drug’ into a proper ‘medicine.’  
Functionalised nanocapsules, ‘stealthy’ nanovectors and other targeted drug delivery 
systems, are the fine flower of galenics. In nanomedicine, the formulation or Galenic 
form is designed to be fully active and involved in the drug’s pharmacodynamics itself.  
As a result, the same drug encapsulated in a nanovector will not be bioequivalent to its 
non-nano counterpart – a consequence which is less due to the size18 than to the 
functionalization of the mode of administration at the level of the individual therapeutic 
agent itself (the size being just one feature of this functional individualization). 
‘Molecular galenics’ entails that one cannot fully distinguish between the active 
substance and the excipients anymore: The formulation is no longer a passive vehicle; 
rather, it acquires its own kind of activity in the organism during the entire drug’s 
trajectory, e.g. by cheating on opsonization (the process by which a pathogen agent is 
marked for ingestion and destruction by a phagocyte), tricking protein-antibody 
molecular recognition, or heating magnetic particles. 
5.2. The Becoming-public of Valuations 
The process of functional individualization of molecular objects brings direct visibility to 
the valuations loaded in the otherwise invisible object. Even if they have to be interpreted 
and appraised, the valuations are no more hidden; they appear directly anchored to the 
object, gravitating around it. CDs are shown operating individually in interaction with 
their milieus, and are no longer a mere ingredient hidden in the bulk formulation of the 
drug or in the mysterious formula of a cleaning product.  
While conferring new valuations to the object, the nano-realm is also operating as a 
discloser for past valuations. Suddenly, the object’s trajectory is rendered visible. For that 
reason, a biography of cyclodextrins may not have been possible before they became 
‘nano’. If nanotechnology renders the invisible visible, it does not show it as something 
that was sitting there for ever; but rather as something that is manifestly half natural, half 
made on purpose, and raises the question of its finality. By accomplishing their ‘nano-
turn’, molecular objects appear somewhat overtly with their valuations. Contrarily to the 
norm that prevailed in the self-image of modern science, in the technoscientific 
nanorealm the objectivity of the object and the values of its uses are no longer separated.  
This makes a huge difference regarding the generation of trust: Trust-valuations become 
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 If we consider the size of a bulk formulation of a drug, a nanovector would be smaller, but if we 
consider the size of a therapeutic molecule alone, it is in fact bigger than it. 
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somewhat publicly observable, and not only limited to scientists, industrials and experts.  
The schema ‘trust in the scientific community versus confidence for the public’ does no 
longer seem acceptable.   
5.3. The Need for Critical Trust 
But the problem is not participation per se; it is not that laypeople necessarily have to be 
involved in upstream engagement, regardless of the character of the technology in 
question. The problem is object-centred: Becoming ‘nano’ reconfigures the character of 
chemical objects. Nano-objects acquire a mode of existence that, in order to be brought to 
completion, appeals to be socially invested and critically appraised. Nano-objects cry out 
for critical trust. 
The new meanings and valuations acquired in the nanoworld may be in contrast or in 
conflict with past valuations. Consider drug formulation when becoming ‘nano:’ 
Traditionally, as Galenics is based on the coupling between the active principle and the 
formulation, it allows mediating the chemical and the social (Rasmussen, 2005). In nano-
medicines, it cannot guarantee this social function anymore. Unlike traditional galenics, 
with nanomedicines the materialisation and the socialisation of the drugs are not 
occurring at the same scale anymore. Mediation is missing, and has to be reinvented.  
New mediations, new valuations have to be found.  
It is important for the purpose of regulation to take into account both the added 
values and the reactivation of past valuations. Consider, for example, the regulatory 
GRAS exemption, allowing CD to be regulated as a food additive. Is it still relevant for 
CDs used in nanomedicines? The concept of nanomedicine requires an re-evaluation of 
classical substances that were previously considered to be simple ingredients and that are 
now designed to be fully active, with every single molecule having a well-defined 
function, contrary to our present medicines operating only following statistic laws; and 
turning CDs into active substances would require a new approval and the end of the 
GRAS exemption. 
6. Conclusion 
This paper advocates the notion of ‘trust in objects’ which is taken into account neither 
by the social theories of trust nor by nanotechnology ELSI studies, which approach trust 
in terms of ‘public perception’ (Åm, 2010).      
We argue that human/objects relationships do involve trust and not just confidence.  
Our case study shows that a firm distinction between trust and confidence can be 
maintained, although they work together. For instance, confidence, or perhaps over-
confidence, is obvious in Szejtli’s repeated criticisms of French’s misinformation as if he 
had betrayed the cause of CDs.  The attempt at producing confidence is also obvious in 
the series of reviews emphasizing the innocuousness, availability and advantages of CDs 
for pharmaceuticals and chemists, even if the CD community was first bestowing trust 
and only thereafter ‘selling’ confidence.  
Does an object become an object of trust ‘by design?’ To be sure, technical (or 
chemical) design can contribute to the construction of trust, but no design can secure 
trust. Trust, unlike reliability, is never acquired once for all. And there is no trust without 
the awareness of a risk. Ironically, Szejtli’s repeated claims for the innocuousness of CDs 
contributed to keeping alive the memory of toxicity.  
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Trust should not be overestimated as a moral or normative concept. Neither should it 
be confounded with trustworthiness (Hardin, 1996) nor mere acceptance. Consequently, 
what has been described as an ‘object of trust’ is not necessarily a ‘good’ object (while an 
object of distrust would be a ‘bad’ one). However, it is no longer a neutral object. It is not 
‘beyond good and evil’, but would be more below good and evil. It would be an object 
that has acquired the ability to be called an object of trust or/and distrust.  
This opens up issues concerning public debates: Rather than to be focused on 
acceptance, or on the ways to gain public’s confidence, should public debate reflect fully 
and explicitly the valuations sustaining the subtle mechanisms of trust? How can this be 
accomplished without provoking a general feeling of ‘ontological insecurity?’ To which 
extent should public trust be transmuted into public confidence by ‘black boxing’ the 
values in the objects? How and who is to decide that? And, what could be a desirable 
‘economy of trust and confidence’ for nanotechnology?  
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